{"type":"trials","record":{"id":41720,"source_id":"clinicaltrials-gov","external_id":"NCT04270747","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","brief_summary":"The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Amgen","enrollment":576,"countries":["United States","Canada","Czechia","Estonia","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Latvia","Lithuania","Mexico","Poland","Serbia","Slovakia","South Korea","Spain"],"start_date":"2020-06-22","completion_date":"2023-01-30","last_update_date":"2025-09-10","source_url":"https://clinicaltrials.gov/study/NCT04270747","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Aflibercept-Treatment Group B1; ABP 938-Treatment group B2","organization":"Amgen","interventions":["ABP 938","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean Change From Baseline in BCVA at Week 8 — Baseline and Week 8","Percentage of Participants Who Maintained Vision at Week 52 — Week 52","Mean Change From Baseline in BCVA — Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52","Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 8 — Week 8","Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 52 — Week 52","Mean Change From Baseline in Choroidal Neovascularization (CNV) Area Size — Baseline and Weeks 8, 16, 24, and 52","Mean Change From Baseline in Central Subfield Thickness (CST) — Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52","Number of Participants With Treatment-emergent Adverse Events (TEAEs) — Up to Week 52","Number of Participants Developing Binding Antidrug Antibodies (ADAs) — Baseline up to Week 52"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":true},"controlled_terms":["Neovascular (Wet) Age-related Macular Degeneration (AMD)","ABP 938","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04270747","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-06-22 to 2023-01-30","comparator":"Aflibercept-Treatment Group B1; ABP 938-Treatment group B2","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.859Z","intervention":["ABP 938","Aflibercept"],"participants":576,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean Change From Baseline in BCVA at Week 8 — Baseline and Week 8","Percentage of Participants Who Maintained Vision at Week 52 — Week 52","Mean Change From Baseline in BCVA — Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52","Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 8 — Week 8","Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 52 — Week 52","Mean Change From Baseline in Choroidal Neovascularization (CNV) Area Size — Baseline and Weeks 8, 16, 24, and 52","Mean Change From Baseline in Central Subfield Thickness (CST) — Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52","Number of Participants With Treatment-emergent Adverse Events (TEAEs) — Up to Week 52","Number of Participants Developing Binding Antidrug Antibodies (ADAs) — Baseline up to Week 52"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41720","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}